Top 50 Life Science Startup Investors in Israel (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Sapir Venture Partners
VC Fund
|
4 | Israel, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, Biotechnology, Machine Learning | $1.3M–$40M |
|
Israel Innovation Authority
VC Fund
|
4 | Israel, United States, Mali | Grant, Seed, Pre-Seed | Health Care, Biotechnology, Medical Device | $100k–$6M |
|
Integra Holdings
VC Fund
|
4 | Israel | Seed, Series B, Series F | Biotechnology, Pharmaceutical, Life Science | |
|
Grove Ventures
VC Fund
|
3 | Israel, United States | Seed, Series A, Series B | Artificial Intelligence, Software, Machine Learning | $3.5M–$74M |
|
Pitango VC
VC Fund
|
3 | Israel, United States, China | Series A, Series B, Series C | Software, Health Care, Information Technology | $4M–$100M |
|
OrbiMed
VC Fund
|
3 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$150M |
|
aMoon Fund
VC Fund
|
3 | United States, Israel, France | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5.7M–$93M |
|
Neo Ventures
VC Fund
|
2 | Israel, United Kingdom, Turkey | Seed, Series A | SaaS, Software, Aerospace | $500k–$2.7M |
|
Johnson & Johnson Robotics and Digital Solutions
VC Fund
|
2 | United States, Israel, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $300k–$100M |
|
First Star Ventures
VC Fund
|
2 | United States, Canada, Israel | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Biotechnology | $575k–$15M |
|
Pontifax
VC Fund
|
2 | United States, Israel, France | Series A, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $4M–$104M |
|
Arancia International
VC Fund
|
2 | Israel, United States, Malaysia | Series A, Series B | Health Care, Biotechnology, Life Science | $7.5M–$17M |
|
Grok Ventures
VC Fund
|
2 | Australia, United States, Singapore | Series A, Seed, Series B | Renewable Energy, Software, Biotechnology | $808k–$150M |
|
Cancer Focus Fund
VC Fund
|
2 | Israel, United States, Germany | Series A, Seed | Biotechnology, Medical, Health Care | $5.4M–$28M |
|
Minrav
VC Fund
|
2 | Israel, Malaysia | Series A | Health Care, Hospital, Wellness | $10M–$10M |
|
Genesis Park
VC Fund
|
2 | United States, Israel | Private Equity, Debt Financing | Construction, Manufacturing, Logistics | $2.5M–$200M |
|
fresh.fund
VC Fund
|
2 | Israel, United States, Norway | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $120k–$21M |
|
PeakBridge
VC Fund
|
2 | Israel, United States, United Kingdom | Series A, Seed, Series B | Food and Beverage, Health Care, Food Processing | $768k–$50M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Takeda Ventures
VC Fund
|
2 | United States, United Kingdom, Israel | Series A, Series B | Biotechnology, Health Care, Therapeutics | $10M–$130M |
|
FutuRx
VC Fund
|
2 | Israel | Seed | Biotechnology, Life Science, Biopharma | |
|
Morningside
VC Fund
|
1 | United States, United Kingdom, China | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $6M–$112M |
|
3B Future Health Fund
VC Fund
|
1 | United States, Italy, United Kingdom | Series B, Series A | Biotechnology, Therapeutics, Medical | $2.7M–$43M |
|
Remiges Ventures
VC Fund
|
1 | United States, Japan, Canada | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $8.1M–$553M |
|
GoodPaper Ventures
VC Fund
|
1 | Series A | Legal, Legal Tech, E-Signature | ||
|
ReGen Ventures
VC Fund
|
1 | United States, Austria, United Kingdom | Seed, Series A, Series B | Agriculture, Biotechnology, Farming | |
|
Terra Venture Partners
VC Fund
|
1 | Israel, United States | Seed, Series A, Series B | Artificial Intelligence, Machine Learning, Software | |
|
Arkin Holdings
VC Fund
|
1 | Israel, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2M–$95M |
|
Pfizer
VC Fund
|
1 | United States, Israel, France | Post-IPO Equity, Series A, Seed | Biotechnology, Health Care, Pharmaceutical | |
|
RMGP Biopharma Investment Fund
VC Fund
|
1 | Israel | Seed, Series B | Biotechnology, Biopharma, Health Care | |
|
RM Global Partners
VC Fund
|
1 | Israel, United States | Series A, Series B | Biotechnology, Health Care, Life Science | $18M–$140M |
|
Trust Ventures
VC Fund
|
1 | United States, Brazil, Israel | Seed, Series A, Series B | Health Care, Software, Information Technology | $3.2M–$200M |
|
Angel
VC Fund
|
1 | United States, United Kingdom, Singapore | Pre-Seed, Seed, Series A | Software, Information Technology, Artificial Intelligence | |
|
Bio Capital Impact Fund
VC Fund
|
1 | Israel | Medical, Health Care, Life Science | ||
|
SICAR
VC Fund
|
1 | Israel, Germany | Series C | Medical, Health Care, Life Science | |
|
Khosla Ventures
VC Fund
|
1 | United States, India, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Health Care | |
|
Arba Finance Ltd.
VC Fund
|
1 | Israel | Series A | AgTech, Medical, Cannabis | |
|
ALIVE Israel HealthTech Fund
VC Fund
|
1 | Israel, United States | Series A, Series B | Health Care, Medical, Biotechnology | |
|
Jerusalem Venture Partners (JVP)
VC Fund
|
1 | United States, Israel, United Kingdom | Series A, Series B, Seed | Software, Cyber Security, Enterprise Software | $1.5M–$43M |
|
Arix Bioscience
VC Fund
|
1 | United States, France, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $20M–$140M |
|
Rationalwave Capital Partners
VC Fund
|
1 | United States, Israel, Trinidad and Tobago | Seed, Pre-Seed | Analytics, Machine Learning, Artificial Intelligence | $1.3M–$8.8M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
1 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
Dementia Discovery Fund
VC Fund
|
1 | United States, United Kingdom, Israel | Seed, Series A | Biotechnology, Health Care, Therapeutics | $5.9M–$77M |
|
Windham Venture Partners
VC Fund
|
1 | United States, Israel | Series B, Series C, Series A | Health Care, Medical, Biotechnology | $4.3M–$100M |
|
Forbion Capital Partners
VC Fund
|
1 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $12M–$176M |
|
Trendlines Group
VC Fund
|
1 | Israel, Singapore, United Kingdom | Seed, Series A | Health Care, Biotechnology, Medical Device | $650k–$15M |
|
Sectoral Asset Management
VC Fund
|
1 | United States, United Kingdom, France | Series B, Series C, Post-IPO Equity | Health Care, Biotechnology, Medical | $20M–$230M |
|
NextLeap Ventures
VC Fund
|
1 | Israel, United States | Seed, Series A | Software, Big Data, Health Care | $900k–$21M |
|
Clal Biotechnology Industries
VC Fund
|
1 | Israel, United States | Series A, Series B | Health Care, Biotechnology, Medical | $4M–$55M |
|
Stony Hill Corp
VC Fund
|
1 | Israel | Series A | AgTech, Medical, Cannabis | |
| Access all 98 investors in Israel Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Early Stage VC
Show more...Investment focus
- Industry: Software, Biotechnology, Machine Learning
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 20
- Round size: Seed $1.3M–$5M; Series A $10M–$40M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
- Lidwave — Lidwave’s deep-tech solution revolutionizes 3D sensing and the verticals relying on it by examining the biggest challenge in LiDAR technology from a new perspective, free of bandwidth limitations.
- DeepCure — DeepCure is a Boston-based therapeutics company that harnesses advanced AI, physics-based tools and automation to discover novel small molecules for challenging targets. DeepCure currently has a lead asset in IND-enabling studies and other programs focused on drugging intractable targets that have t
The Israel Innovation Agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Grant, Seed, Pre-Seed
- Geography: Israel, United States, Mali
Investor stats
- Total investments: 141
- Round size: Seed $590k–$6M; Grant $100k–$3.5M; Pre-Seed $150k–$2.5M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Q-Factor —
- Sub-Q Bionics — Sub-Q Bionics is a medtech company, that aids the management of chronic pain and debilitating symptoms of lymphedema specially for women.
- Scala Biodesign — At Scala Biodesign, we provide our partners a unique one-shot computational protein design solutions to dramatically increase the value and accelerate the development of proteins into commercial products.
Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Life Science
- Stage:Seed, Series B, Series F
- Geography: Israel
Investor stats
- Total investments: 8
- Lead/follow: 75% lead, 25% follow
Portfolio highlights
- BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
- Splisense — Transformative RNA Based Treatments -Antisense Oligonucleotides- Targeting the Root Cause of Pulmonary Diseases Our innovative RNA based therapies, based on Antisense Oligonucleotides (ASOs), restore and modify protein functionality, addressing untreatable pulmonary diseases.
- Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria
Grove Ventures is a leading early-stage venture capital fund in Israel. It partners early with exceptional Israeli founders who believe th...
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 68
- Round size: Seed $3.5M–$20M; Series A $8M–$50M; Series B $20M–$74M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- Niv-AI — Niv-AI develops an AI platform that optimizes power usage in AI data centers by capturing real-time electricity consumption data and dynamically balancing workloads. It addresses bottlenecks where synchronized GPUs create sharp power spikes, unlocking up to 30% of stranded capacity without new hardware.
- NoTraffic — NoTraffic has developed the first AI-powered traffic signal platform that connects road...
- Scala Biodesign — At Scala Biodesign, we provide our partners a unique one-shot computational protein design solutions to dramatically increase the value and accelerate the development of proteins into commercial products.
Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Series B, Series C
- Geography: Israel, United States, China
Investor stats
- Total investments: 277
- Round size: Series A $4M–$47M; Series B $7.5M–$44M; Series C $8.2M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $175M in 2023
Portfolio highlights
- Nexite — Nexite develops a platform that provides item tracking, inventory transparency and business intelligence from manufacturing to the customer's home. Its miniature NanoBT batteryless tag can be read by any smartphone, costs a fraction of the cost of similar tags, and is small enough to embed into the item. The company was founded in 2017 andis headquartered in Tel Aviv, Israel.
- Sayata — Sayata delivers rapid growth to brokers and carriers that place commercial risk.The Sayata platform streamlines the quote-bind-issue process allowing insurance professionals to seamlessly place commercial risk in a fraction of the time.Sayata provides an end-to-end technological solution along with educational tools, giving our partners theability to grow their book quickly and efficiently.To date, over 1,000 users across 75 brokerages and carriers partner with Sayata to grow their commercial book.
- Topspin Medical — TopSpin Medical developed an innovative and unique technology for high-resolution MRI using an IntraVascular MRI (IVMRI) catheter for the coronary arteries, without the need for an expensive and bulky external MRI setup. The catheter contains those components, which are usually found in a conventional MRI scanner, only that they are miniaturizedto less than 2 millimeters in size.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 576
- Round size: Series A $10M–$116M; Series B $24M–$150M; Series C $15M–$131M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- resTORbio — Restore Beauty - Rethink Bio
- Caris Life Sciences — Caris fulfills the promise of precision oncology through advanced laboratory testing, including tumor profiling and blood-based cancer diagnostics.
aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 75
- Round size: Series A $5.7M–$83M; Series B $22M–$93M; Series C $30M–$82M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Lin Health — Online chronic pain recovery program designed to get you back to the life you want to live. One-on-one coaching. Real pain reduction results.
- KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
Neo Ventures is the first open-ended early stage investor, based in Eastern Europe. The founders have backed more than 30 startups and exited 10 successfully. We invest in game-changing businesses, without geographic limitations. We partner with exceptional founder teams to challenge incumbents in markets ripe for change or to create entirely newmarkets. Neo Ventures funds and then supports the founders in business planning, scaling operations, follow-on investments, making the best of each opportunity and dealing with hard situations. Our investment focus is on data analytics, computer vision and remote sensing addressing disruptive opportunities across the high-growth SpaceTech, BioTech and Security verticals.
Show more...Investment focus
- Industry: SaaS, Software, Aerospace
- Stage:Seed, Series A
- Geography: Israel, United Kingdom, Turkey
Investor stats
- Total investments: 14
- Round size: Seed $500k–$1.7M; Series A $2.3M–$2.7M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Bulbi — Bulbi is a child development platform designed to help parents discover online and face-to-face educational activities for their children.
- EnduroSat — At EnduroSat, we engineer, build and operate exceptional satellites. Our Mission is to make space universally accessible.
- Cyberwrite — AI-powered cyber insurance intelligence platform that transforms raw data into explainable, defensible financial decisions.
Healthcare innovation wherever it originates.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 70
- Round size: Series A $5.9M–$63M; Series B $18M–$55M; Series C $300k–$100M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Moon Surgical — Create the OR of the future, one that is sustainable, efficient, and digitalized.
- Artera — Discover the power of Personalized Precision Medicine & AI Cancer Therapy with Artera. Transforming cancer therapy through innovation.
- ONL Therapeutics — ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Investing with conviction in visionary, technical founders inventing the future.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 59
- Round size: Seed $1M–$8.5M; Pre-Seed $575k–$1.8M; Series A $4.2M–$15M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- SaolaAI — SaolaAI is the go-to platform for zero-maintenance, maximum-coverage quality, powered by real user behavior insights. With over 30 million user sessions recorded, SaolaAI stands at the forefront of autonomous quality, trusted by hundreds of engineering teams to catch critical issues throughout the application lifecycle, ensuring top-notch productquality with ease.
- Kanary — Established in 2020 by U.S. campaign security and data science experts, Kanary finds, removes, and monitors your information across search engines, data brokers, and social media.
- Blumen Systems — Blumen is an early-stage technology company building software to streamline the regulatory challenges associated with upstream natural resources production in the US. We are focused on producers building and utilizing land-based assets powering the energy transition including carbon sequestration, geothermal, critical minerals, hydrogen, and RNGprojects.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 106
- Round size: Series A $4M–$95M; Series B $20M–$100M; Series C $12M–$104M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $14M in 2020
Portfolio highlights
- Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
Arancia International Inc is a part of Arancia Group in Mexico. We are long term investors in food, nutrition and biotechnology companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Series A, Series B
- Geography: Israel, United States, Malaysia
Investor stats
- Total investments: 9
- Round size: Series A $10M–$17M; Series B $7.5M–$11M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- NextFerm — NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value.At Nextferm, they aim to use their capabilities to lead this new and exciting world of better nutrition.
- iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
- The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.
Backing a better tomorrow
Show more...Investment focus
- Industry: Renewable Energy, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 66
- Round size: Seed $808k–$10M; Series A $3.3M–$63M; Series B $12M–$150M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Spriggy — Spriggy is a mobile app with a linked prepaid card that helps kids learn the concept of digital money.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
- August Robotics — August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment
Cancer Focus Fund is an oncology-focused investment firm advancing breakthrough cancer therapies by partnering with leading scientists, institutions and early-stage companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: Israel, United States, Germany
Investor stats
- Total investments: 10
- Round size: Series A $5.4M–$28M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $50M in 2019
Portfolio highlights
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces march.biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity of
- Starget Pharma — Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues.
- Nectin Therapeutics — NectinTX develops next-generation delivery platforms for immuno-oncology and precision therapeutics. Discover breakthrough protein expression technologies that power safer, more effective treatments.
Minrav provides engineering and construction services.
Show more...Investment focus
- Industry: Health Care, Hospital, Wellness
- Stage:Series A
- Geography: Israel, Malaysia
Investor stats
- Total investments: 4
- Round size: Series A $10M–$10M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
- Qualitas Health — Qualitas Health Group aims to serve patients through a network of 500 clinics by 2022 with quality healthcare services across the Asia Pacific.
Genesis Park is a Houston-based private equity firm focusing on buyouts, partnering strategies with public corporations, and growth financing. We bring capital, commercial execution capabilities and a depth of experience in mergers and acquisitions.We are opportunistic within market sectors where we have depth and exposure. Those sectors includetelecommunications, energy technology and media. Energy technology is a rapidly expanding category, and our Houston base allows us to marry traditional and alternative techniques in upstream and downstream environments. Founded in 2000, Genesis Park has used discipline and patience to build value for our investors, regardless of prevailing market conditions. We are consistently active in our portfolio companies, listening, learning and adding value by working alongside management. While our preference is to partner with an existing management team, we commonly source additional talent to optimize the existing opportunity.
Show more...Investment focus
- Industry: Construction, Manufacturing, Logistics
- Stage:Private Equity, Debt Financing
- Geography: United States, Israel
Investor stats
- Total investments: 19
- Round size: Debt Financing $5.5M–$65M; Private Equity $2.5M–$200M
- Lead/follow: 58% lead, 42% follow
- Last fund: Likely still investing — raised $275M in 2021
Portfolio highlights
- The Good Feet Store — Go beyond insoles with arch supports designed to support your feet and help relieve foot, knee, hip, and back discomfort. Visit a store near you.
- Conditioned Air — Conditioned Air offers air conditioning contractor, AC and heating services for residential and commercial sectors.
- GLASS BOX TECHNOLOGY INC — Glass Box Technology Inc offers customizable network, storage, security, and server solutions designed to meet the needs of the industries.
fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: Israel, United States, Norway
Investor stats
- Total investments: 41
- Round size: Seed $3M–$12M; Pre-Seed $120k–$6M; Series A $11M–$21M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Wisio — Wisio lets social media creators and experts answer questions and requests from followers via paid interactions. The company’s platform empowers followers to gain exclusive access via personalized videos to their favorite creators. Wisio's flexible and easy-to-use platform is packed with features to help creators build deeper communitieswhile monetizing the creator - follower relationship. Thousands of them are already using it to help build their online reputation and business.Wisio's vision is to make everyone reachable.
- Clearitty — Clearitty - The Ultimate Sales Accelerator by Turning Deal Insights into Revenue We provide the tools and insights for sales executives to close deals faster and outperform competitors, empowering you to drive growth and success. It’s free to start — no trial, no contract, no risk.Clearitty was born out of a shared frustration experienced bysales executives and entrepreneurs alike – the lack of critical insights about new buyers. These invaluable insights are often held by those who have successfully navigated the sales process with these coveted clients.Recognizing the gap, in 2022 we created Clearitty, dedicated to developing an intelligence tool that helps sales executives shorten sales cycles and close deals more efficiently.Our goal is to build the world’s largest database of buyer insights, empowering sales executives with the knowledge they need to succeed.
- Sherloq — Ask your SQL anything. Built on your context, directly on your editor.
PeakBridge is a highly networked, global impact VC that funds and connects the people, technology and processes that will shape the future of food. We invest in visionary pioneers, from early stage to Series A-B, with scalable, protectable climate and health-focused technologies. At their core: a deep commitment to disrupting our food system whiledriving positive impact. Our team is spread across seven countries and includes pioneers of FoodTech investment and decades of deep Agri-Food operational and financial experience. Together, we create exceptional value for bold FoodTech entrepreneurs and investors. A member of the Edmond de Rothschild Private Equity partnership, PeakBridge is also the only venture capital firm that is an official partner of the world’s largest Agri-Food innovation initiative, EIT Food.
Show more...Investment focus
- Industry: Food and Beverage, Health Care, Food Processing
- Stage:Series A, Seed, Series B
- Geography: Israel, United States, United Kingdom
Investor stats
- Total investments: 46
- Round size: Seed $768k–$11M; Series A $4.9M–$17M; Series B $11M–$50M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $106M in 2022
Portfolio highlights
- SOUS — One easy-to-use tool to grow traffic, make online sales, seamlessly handle orders and drive retention. Built for food entrepreneurs, built with taste.
- Tastewise — Tastewise is a consumer intelligence platform transforming food insights with AI. Discover trends, predict preferences, and drive innovation
- Rival Foods — We craft food we feel good about - Protein foods without compromises! At Rival Foods we create whole-cut specialties with remarkable texture, taste and juiciness, the ideal proposition for food professionals to create new plant-based eating experiences. Ready to use in all your favorite dishes! Interested in our products?
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 103
- Round size: Series A $10M–$58M; Series B $20M–$130M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
- Accipiter Biosciences — Accipiter Biosciences is a biotechnology company.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.
Show more...Investment focus
- Industry: Biotechnology, Life Science, Biopharma
- Stage:Seed
- Geography: Israel
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
- Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
- Bsense Bio Therapeutics — Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety.
Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically.Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology.Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 106
- Round size: Series A $6M–$45M; Series B $13M–$100M; Series C $9.2M–$112M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Geneoscopy — Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications.
- Aural Analytics — Powerful brain health analytics that are clinically interpretable, reliable, precise and objective. Award winning and validated by key industry leaders.
- Vesigen Therapeutics — Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes(Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets.
Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series B, Series A
- Geography: United States, Italy, United Kingdom
Investor stats
- Total investments: 31
- Round size: Series A $2.7M–$43M; Series B $7.9M–$40M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- On Target Laboratories — ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.
Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, Japan, Canada
Investor stats
- Total investments: 23
- Round size: Seed $10M–$42M; Series A $8.1M–$85M; Series B $8.2M–$553M
- Lead/follow: 65% lead, 35% follow
- Last fund: May invest from a new fund soon — raised $95M in 2019
Portfolio highlights
- Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
- KisoJi Biotechnology — KisoJi is a leading next-generation antibody company developing multi-specific antibodies to address difficult targets in oncology and other diseases
- Restore Vision — Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.
GoodPaper Ventures is a venture capital company that offers private equity and investment management services.
Show more...Investment focus
- Industry: Legal, Legal Tech, E-Signature
- Stage:Series A
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- OneNotary — Looking for a reliable and convenient on-demand online notary service? OneNotary platform offers fully legal and secure notarization services in all 50 states.
- Foresee Genomics — Foresee Genomics brings high-precision NGS to every lab with fast, affordable diagnostics that advance personalized care and unlock growth.
Investing in the ReGeneration
Show more...Investment focus
- Industry: Agriculture, Biotechnology, Farming
- Stage:Seed, Series A, Series B
- Geography: United States, Austria, United Kingdom
Investor stats
- Total investments: 19
- Lead/follow: no public data
Portfolio highlights
- Anthrogen — Anthrogen is a Biotechnology Research firm using bacteria and enzymes for reducing carbon in the air by transforming it into chemicals.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
- Differential Bio — Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.
We are an early stage venture capital firm dedicated to partnering with inspiring entrepreneurs to build breakthrough companies
Show more...Investment focus
- Industry: Artificial Intelligence, Machine Learning, Software
- Stage:Seed, Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 41
- Lead/follow: no public data
Portfolio highlights
- ViewNetic — ViewNetic is an AgTech startup developing unique imaging and machine learning technologies for early, pre-propagation detection of pests and diseases in high-value crops.
- Infiniplex — Infiniplex is an Israel-based startup whose mission is to utilize routine blood testing to screen for genetic tumor biomarkers and to offer preemptive, preventive, and follow-up cancer screenings at a more accessible and affordable cost. Our goal is to identify common and rare cancer types through a standard, inexpensive blood test that could becarried out as part of routine checkups, leveraging existing laboratory equipment and know-how. We aim to include tumor genomic testing as part of people's standard blood test checkups. The company was founded in 2021 and is based in Yokne'am Illit, Israel.
- Intuition Robotics — The AI care companion robot for older adults
Explore Arkin Capital: A leading multi-asset manager driving strategic investments across health, technology, equity, real estate and more
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: Israel, United States, Switzerland
Investor stats
- Total investments: 31
- Round size: Seed $2M–$6M; Series A $15M–$29M; Series B $23M–$95M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $270M in 2021
Portfolio highlights
- Lendbuzz — Lendbuzz is an AI-based auto finance platform that helps consumers with thin or no credit history obtain financing when purchasing a car. Powered by machine learning and proprietary algorithms, Lendbuzz is able to better assess the creditworthiness of consumers with limited credit history, who are underserved by the traditional banks. By partneringwith auto dealerships, Lendbuzz is able to offer consumers attractive financing solutions and dealerships are able to close additional business opportunities and serve a more diversified client base. Lendbuzz is headquartered in Boston, Massachusetts and was founded in 2015.
- Phytolon — Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
- Nocion Therapeutics — Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation.
Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Post-IPO Equity, Series A, Seed
- Geography: United States, Israel, France
Investor stats
- Total investments: 53
- Lead/follow: no public data
Portfolio highlights
- CytoReason — CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases,reduce development costs and increase the likelihood of approval. To date, six of the world’s top ten pharma companies use CytoReason’s technology.
- AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
- EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
RMGP Biopharma Investment Fund is an investment Fund
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Health Care
- Stage:Seed, Series B
- Geography: Israel
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
- Pi Therapeutics — Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and hasoperated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
- Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!RM Global is an investment banking and strategic advisory firm dedicated to creating unique value for its clients and investors. We specialize in Life Sciences, including pharmaceuticals, medical devices, biotechnology, healthcare IT/digital health, and diagnostics. Our broad international reach includes the Americas, Europe, Israel, and Asia.Since 1992, our diverse team of accomplished professionals has worked closely with life science companies ranging from start-ups to multinationals, providing unbiased strategic and financial advice, based upon our comprehensive industry experience. Several of our partners were senior management of Roberts Mitani, which completed over $3 billion in M&A and strategic transactions and raised over $200 million in private growth and venture capital for clients. We take pride in our long term relationships with our clients that span many years.We leverage our unique global network of leading corporations, investment funds, institutional and strategic investors, family offices, industry experts and management teams to source and execute transactions that build new opportunities for our clients worldwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 4
- Round size: Series A $18M–$20M; Series B $32M–$140M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $64M in 2019
Portfolio highlights
- BIOMx — BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
- Mitoconix Bio — Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism,keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constantly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death.Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).
- ImmPACT Bio — ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
Trust Ventures is a venture capital firm that focuses on startups and provides knowledge and expertise in incumbent-heavy industries. The firm was founded in 2018 and is based in Austin, Texas, United States.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Brazil, Israel
Investor stats
- Total investments: 58
- Round size: Seed $3.2M–$23M; Series A $10M–$50M; Series B $9M–$200M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Base Power — Base provides a battery-powered home energy service so you can enjoy power without interruption and save money. Now available in select regions of Texas.
- Voya Energy — Voya Energy is an energy management company that has developed technology to transform high-energy recycled metals into a safe fuel.
- StellarFi — We Pay Your Bills, So YouCan Build Credit. With Stellar your bills are paid on time and on your terms.
Angel
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Pre-Seed, Seed, Series A
- Geography: United States, United Kingdom, Singapore
Investor stats
- Total investments: 61
- Lead/follow: no public data
Portfolio highlights
- Vytal.ai — Vytal allows for brain health evaluation in minutes with just a laptop. Take control of your cognitive health.
- Akhetonics — Creating the first all-optical RISC Processor
- Greena World — In a world where travel connects us, we often overlook the impact we leave behind. Tourism accounts for over 8% of global CO2 emissions. Beyond environmental challenges like deforestation, pollution, and water scarcity, local communities also face pressure, experiencing changes in their traditions and ways of life.With expertise from SwanseaUniversity and the United Nations, our team recognised these challenges and envisioned a world where travel helps, not harms. Introducing Greena World. More than just a piece of technology, it's a guide for hotels and restaurants, helping them understand, improve, and share their impact on both the environment and local communities.The true beauty of embracing sustainability? The rewards. With the Greena Index, businesses can improve their sustainability and, in doing so, unlock a new market of over 100+ million eco-conscious travellers, boost revenues, and save on operating costs.The sustainable tourism sector is rapidly expanding, currently valued at $75B and witnessing a growth rate of 9.7% each year. While our initial focus is on hotels and restaurants, the Greena Index has ambitions to reshape the entire spectrum of the industry, from airlines to activities and destinations.Join us on a mission to transform the entire tourism industry for many generations to come.
Global impact fund focusing on biotech, medtech and agritech investments that make a difference
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Geography: Israel
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
SICAR
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series C
- Geography: Israel, Germany
Investor stats
- Total investments: 2
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
- OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Series B, Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 981
- Lead/follow: no public data
Portfolio highlights
- Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
- Vectra AI — Vectra is the world leader in AI threat detection and response. The Cognito platform uses AI to detect attackers in real time and perform conclusive investigations.
- Point One Navigation — Precise Positioning for the next generation of transportation. 10cm accuracy everywhere.
An investment banking boutique, founded in 1978
Show more...Investment focus
- Industry: AgTech, Medical, Cannabis
- Stage:Series A
- Geography: Israel
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- GemmaCert — GemmaCert is a smart solution for testing cannabis potency, which unlike other solutions, is simple and sleek, for everyday use, requiring no specific skill-set for operation, and whose form gives little indication to the sophistication of the technology working underneath. GemmaCert is a bridge between technology and nature. This design createdthe desired attractive and useful man-machine interface for the best possible user experience along with a well-defined product with aesthetic presence without sacrificing on performance. GemmaCert is making a name for high performance, robustness, ease-of-use and reliability.No cannabis flower is the same, so before anyone consumes cannabis, they should have an understanding exactly what is in it and how it may affect them. From pharmacies in Germany, coffeeshops in Amsterdam, to supply chain stakeholders in North America, GemmaCert brings certainty and confidence to cannabis professionals, as well as consumers and patients worldwide.After over two years in research and development, GemmaCert started delivering first units to customers worldwide, primarily in North America and Europe. Revenues are generated from device sales and monthly subscription fees to our analytical service since GemmaCert units are operated and upgraded via secure cloud-based servers.
ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- Wisdo Health — Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health.
- Vessi Medical — Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer (NMIBC).
- Gina Life — At Nevia bio, we are focused on women's health. Our mission is to use innovative technologies to provide early detection of diseases through vaginal secretions analysis, enabled by Nevia's Machine Learning Platform.
JVP is a top VC firm with $1.9B AUM and 165 companies built, leading in AI, Cyber Security, Fintech, Insurtech and Climatech.
Show more...Investment focus
- Industry: Software, Cyber Security, Enterprise Software
- Stage:Series A, Series B, Seed
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 175
- Round size: Seed $1.5M–$7M; Series A $4.3M–$24M; Series B $10M–$43M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- SENCROP — Sencrop is an ag-tech startup that offers an in-field data-based platform to empower farmers to make better decisions in their daily agricultural activities. Sencrop designs and sells connected weather forecast solutions for farmers to measure rain, hygrometry, and wind speed. The sensors are cheap, robust, movable, and easy to use, making moreefficient and sustainable farming possible
- Source Defense — Source Defense provides an entirely new solution, leveraging a fully automated, machine-learning-assisted set of policies that ensure 3rd party JavaScript integrations operating on your website maximize user experience and eliminate the threat of such integrations being leveraged for malicious website activity.
- Pyramid Analytics — The Pyramid Decision Intelligence Platform is built to power faster and sharper decisions. Learn how it can improve your business decisions.
Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, France, Israel
Investor stats
- Total investments: 32
- Round size: Series A $20M–$58M; Series B $45M–$137M; Series C $53M–$140M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
- Disc Medicine — Committed to turning scientific discoveries into effective medicines that will disrupt the current standard of care, alleviate suffering, and have a meaningful impact on the lives of patients and their families.
- Harpoon Therapeutics — Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, orantigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Rationalwave Capital Partners is a venture capital firm investing in technology companies both public and private. The firm is located in New York and founded by Mark Rosenblatt in 2003.
Show more...Investment focus
- Industry: Analytics, Machine Learning, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: United States, Israel, Trinidad and Tobago
Investor stats
- Total investments: 12
- Round size: Seed $1.3M–$8.8M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Aromyx — Aromyx pioneers the creation of tastes and smells using a quantitative measurement system developed with biotechnology, data science, and AI.
- Brij — With one-touch, BRIJ allows consumers to gain product info, care instructions and discounts while you gain a deeper understanding of your consumer. Apps, paper manuals and hassles not required.
- BactoByte LTD — BactoByte aims to empower caregivers with one-hour bacterial diagnostics and antibiotic screening capability to improve outcomes, reduce mis-diagnostics, and lower health care costs.Based on a proprietary novel basic method, BactoByte’s assay delivers precise and cost-effective identification and direct antibiotics susceptibility testing with80-90% improvement of standard turnaround time.Time reduction, sensitivity, and specificity results in decreased mortality rates, fewer hospital days, and avoidance of associated costs of $1K-50K per patient.BactoByte has technology validation and partnerships with leading medical centers.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 94
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 49
- Round size: Seed $5.9M–$20M; Series A $7M–$77M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $337M in 2018
Portfolio highlights
- QurAlis — QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS .
- Nitrase Therapeutics — Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
- Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.
We focus on advances in medical technology and digital health to change the face of healthcare.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series C, Series A
- Geography: United States, Israel
Investor stats
- Total investments: 61
- Round size: Series A $4.3M–$100M; Series B $7M–$75M; Series C $12M–$73M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- PainTEQ — Explore PainTEQ's innovative solution for SI joint pain. Learn about the LinQ minimally invasive SI joint stabilization procedure, patient success stories, and our commitment to improving quality of life.
- TailorMed — Moving Mountains for Patients
- ClarVista Medical — ClarVista Medical is a developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing, ClarVista was spun out from Prospex Medical, a medical device incubator, to pursue the development of the HARMONI™ IOL. Between 2012 and 2014, the company developed the first generation HARMONI™system, conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system, conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 171
- Round size: Series A $14M–$176M; Series B $12M–$155M; Series C $12M–$113M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A
- Geography: Israel, Singapore, United Kingdom
Investor stats
- Total investments: 67
- Round size: Seed $650k–$3.2M; Series A $2.3M–$15M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- IBI-Ag — IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost.
- Celleste Bio — Celleste is a business that specializes in employing cell culture techniques to produce high-value cocoa ingredients, removing the need for cocoa trees to be grown.
- Arcuro Medical — Arcuro develops a new repair system for meniscus tears of the knee. Arcuro’s proprietary SuperBall repair system consists of a knotless, all-suture anchor and innovative delivery system. The company was founded in 2013.
Sectoral is specialized in managing equities globally in the healthcare sector. Founded in October 2000, we are SEC-registered as an investment advisor. 100% employee-owned, we have offices in Montreal, Geneva, and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 58
- Round size: Series B $20M–$80M; Series C $39M–$115M; Post-IPO Equity $23M–$230M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Iantrek — Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York.
- CurvaFix — Curvafix is the only intramedullary implant that follows the natural curvature of the pelvis. Continue reading to learn how the Curvafix implant works!
- Magnolia Medical Technologies — Magnolia Medical Technologies, proud makers of the Steripath Micro Initial Specimen Diversion Device for blood culture testing integrity.
NextLeap Ventures offers investors the opportunity to invest in early stage, Israeli high-tech startups, selected through its unique, highly vetted process.
Show more...Investment focus
- Industry: Software, Big Data, Health Care
- Stage:Seed, Series A
- Geography: Israel, United States
Investor stats
- Total investments: 16
- Round size: Seed $900k–$5M; Series A $5.3M–$21M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Carrar — A complete thermal management solution for electric vehicles dissipating heat faster and more efficiently than ever before. Thermal management for ev batteries.
- Cybord — Cybord develops technologies that stop counterfeit, defective and malicious electronic components from getting assembled into products during the manufacturing process. Cybord scans each component prior to placement by integrating with electronic product manufacturing equipment, and deep learning algorithms rate each component based on Cybord’sglobal component database. Between 5 to 10% of all electronic components are considered counterfeit, responsible for up to 35% of RMAs. With Cybord, OEMs, EMSs, and distributors ensure their products are of high quality and free of hardware-cyber threats
- Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI).
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Israel, United States
Investor stats
- Total investments: 14
- Round size: Series A $4M–$55M; Series B $15M–$33M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Sight Diagnostics — Combining AI and breakthrough hardware to bring lab-quality CBC results to the doctor's office.
- Cadent Therapeutics — Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts.
- Elicio Therapeutics — Elicio ground-breaking Amphiphile technology is engineering potent vaccines and immunotherapies to defeat an array of aggressive cancers.
A Diversified Company focused on multiple area of the cannabis hemp and CBD industry.
Show more...Investment focus
- Industry: AgTech, Medical, Cannabis
- Stage:Series A
- Geography: Israel
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.
Life Science Investor funding in Israel at a glance
Stats across 69 deals from 98 investors.
Access all 98 investors in Israel Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Israel investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 98 investors investing in Israel Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!